BPC-157: FDA, Compounding & WADA Status

FDA approval status

BPC-157 is not an FDA-approved drug. There is no new-drug approval that authorizes a human therapeutic use. A 2026 review also notes the absence of an approved formulation and a validated dosing regimen.^7,1

A two-participant pilot does not change that status. Neither does an advisory-committee meeting.⁸

In July 2026, some texts read the PCAC as if FDA had “approved” or “legalized” BPC-157. That reading confuses advice with a decision, and compounding with drug approval. This page exists, in part, to undo that confusion.

What happened at the July 2026 PCAC meeting?

On 23–24 July 2026 the Pharmacy Compounding Advisory Committee met. On 23 July the committee discussed BPC-157-related bulk drug substances — BPC-157 free base and BPC-157 acetate — being considered for inclusion on the 503A Bulks List.¹

An advisory committee provides independent, non-binding advice to FDA. The meeting page itself states that recommendations do not legally bind the Agency.¹

Four acts should stay separate. First, FDA staff scientific review of the nomination. Second, the committee’s advisory recommendation. Third, any later formal rulemaking with public comment. Fourth, drug approval. 23 July was not the fourth. It was also not, by itself, the third.^1,2

Regulatory trade press reported a vote of 8 in favor, 6 against, and 1 abstention to recommend inclusion of the forms discussed. That tally is cited here as press reporting, not as official FDA minutes, and it describes an advisory recommendation. A recommendation does not list the substance, does not approve the peptide, and does not legalize a general use.⁴

What the proceeding evaluated

The use official meeting materials identify for BPC-157 free base and acetate is ulcerative colitis. It is not “every internet use,” tendon injury, or sports recovery.¹

Evaluating an ulcerative-colitis compounding nomination does not mean FDA recognizes BPC-157 as an effective therapy for that disease. Staff review is an analysis of the nomination; presentation materials exist in that frame.^1,3

Compounding status

The 503A bulk-substance list is a United States compounding framework, distinct from new-drug approval. Discussing whether a nominated substance might enter that list is not approval of BPC-157, and it is not “FDA approved compounding” as if that were a broad authorization.^1,2

Until a final rule exists, a committee recommendation does not by itself change the peptide’s approval status. This page does not advise how to compound, and it does not advise how to evade rules.

Even if, in the future, a substance entered a compounding list, that would not make it an approved drug and would not prove that it works for ulcerative colitis or for any other use. Compounding and new-drug approval remain different paths.¹

WADA

WADA’s 2026 Prohibited List, in force from 1 January 2026, includes in class S0 pharmacological substances with no current approval by a governmental regulatory health authority for human therapeutic use. In that class the list names BPC-157 explicitly as an example — “including but not limited to BPC-157” — among other non-approved substances.^5,6

S0 covers non-approved substances. BPC-157 is not left only in a generic bucket: it is cited by name. Anyone competing under anti-doping rules should verify the current official list, because lists change by year.

Anti-doping status is not a medical decision and not a regulatory approval. Being prohibited in sport does not by itself “prove” clinical danger, and lacking drug approval is not solved because an athlete is searching for the substance. This page does not discuss detection, windows, or ways to evade a test.

United States versus Mexico

• FDA regulates drugs and compounding in the United States. Its July 2026 meeting is not Mexican law.
• WADA publishes an international anti-doping standard. That is also not a Mexican marketing-authorization rule.
• This page does not make unsupported COFEPRIS claims.
• Peptra situates the material as laboratory research use, not as a medicine.

For human evidence, what exists in humans. For the origin of the colitis nomination, gastrointestinal models. The map is the BPC-157 hub.